This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Gilead Suffers First Hep C Drug Setback

Updated with new information, current stock price.

FOSTER CITY, Calif. ( TheStreet) -- Gilead Sciences (GILD - Get Report) just had its first stumble in the race to develop an all-oral therapy for hepatitis C.

A two-drug regimen of Gilead's experimental GS-7977 plus ribavirin failed to suppress the hepatitis C virus in a group of difficult-to-treat patients who had also failed prior therapy, Gilead announced Friday.

Gilead's GS-7977 streak as the ultimate, flawless hepatitis C drug has now ended. Friday's negative results are a setback and not a fatal blow to the drug's future. However, Gilead spent $11 billion to gain control of GS-7977 through the acquisition of Pharmasset so any failure, no matter how small, is being magnified in the eyes of investors.

Gilead shares plunged 16% to $45.85 in Friday pre-market trading while investors bid up share in other hepatitis C drug stocks, including Idenix Pharmaceuticals (IDIX), Achillion Pharmaceuticals (ACHN) and Vertex Pharmaceuticals (VRTX - Get Report).

Achillion is the biggest gainer Friday, up 20% to $10.52, because the company is developing two drugs -- a protease inhibitor and an NS5A inhibitor -- that may now play more important roles in future all-oral hepatitis C regimens. Achillion, like Idenix, has been mentioned as a potential takeover target..

In this study, ten hepatitis C genotype 1 patients with a prior "null" response to interferon and ribavirin were treated with a combination of GS-7977 plus ribavirin for 12 weeks. Within four weeks of completing treatment, six of eight patients relapsed, meaning the hepatitis C virus, which had been suppressed, came roaring back. Two patients have not relapsed, however they have only reached the two week post-treatment time point, Gilead said.

Null responders are among the most difficult to treat hepatitis C patients because prior therapy has not worked for them.

"These data answer an important question about the use of GS-7977 and ribavirin for the treatment of genotype 1 null responder patients, suggesting that additional direct acting antivirals may be necessary to effectively treat this patient population," said Norbert Bischofberger, Gilead's research chief, in a statement.

GS-7977 is a so-called nucleotide polymerase inhibitor, a potent class of hepatitis C drug believed to have a high barrier to viral resistance. This means the virus has a difficult time mutating or changing into forms that can fight off the drug. Friday's negative data, however, has raised questions about just how effective these "nukes" might be.

Genotype 1 is the predominant form of hepatitis C found in North America and Europe. It's also the most difficult form of the disease to treat. On a call with investors Friday morning, Gilead executives said the company is exploring further ways of treating genotype 1 patients, including adding other direct-acting antiviral drugs to the GS-7977-ribavirin combination or perhaps treating patients longer.

Further data on GS-7977 is coming soon, including important results from a study testing the drug in combination with ribavirin in genoptype 1 patients who have not been previously treated. Gilead is also studying GS-7977 in combination with an experimental drug from Bristol-Myers Squibb (BMY - Get Report).

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $70.97 -1.40%
GILD $87.19 -2.00%
IDIX $24.50 0.20%
VRTX $81.28 -2.10%
AAPL $93.98 0.36%


Chart of I:DJI
DOW 17,706.84 -184.32 -1.03%
S&P 500 2,060.81 -20.62 -0.99%
NASDAQ 4,767.9820 -49.6120 -1.03%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs